Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | Arşiv | Yayın Arama | Yazarlara Bilgi | Etik Politikalar | İletişim  
2015, Cilt 45, Sayı 2, Sayfa(lar) 068-074
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Evaluation of Antimicrobial Resistance Rates of Klebsiella Isolates
Hakan TEMİZ1, Erdal ÖZBEK2, Demet GÜR VURAL1, Tuncer ÖZEKİNCİ3
1Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Mikrobiyoloji Kliniği, Diyarbakır
2Diyarbakır Kadın Doğum ve Çocuk Hastalıkları Hastanesi, Mikrobiyoloji Kliniği, Diyarbakır
3Dicle Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Diyarbakır
Keywords: Antimicrobial resistance, ESBL, Klebsiella spp.

Objective: The aim of this study was to determine the antimicrobial resistance rates of Klebsiella strains which were isolated from various clinical samples sent to the medical microbiology laboratory of our hospital.

Material and Method: The resistance rates of Klebsiella strains to various antibiotics were investigated, retrospectively. The study included 507 Klebsiella strains that were isolated from various clinical samples and accepted as pathogens during 2012-2014 years. The identification and antibiotic susceptibility tests of the isolated bacteria were performed by VITEC 2 ID-AST (bioMérieux, France) and the results were evaluated according to the standards of Clinical and Laboratory Standards Institute.

Results: In this study, 479 (94.5%) of the Klebsiella isolates were identified as Klebsiella pneumoniae while 28 (5.5%) were identified as Klebsiella oxytoca. The strains were isolated from (n=208; 41%) from urine, blood (n=121; 23.9%) tracheal aspirate (n=83; 16.4%), wound sites (n=76; 15%) and other sources (n=19; 3.7%). Of the 507 Klebsiella isolates 330 (65.1%) were detected as ESBLpositive. Amikacin and imipenem were found to be the most effective antimicrobials in vitro for ESBL producing and nonproducing isolates. Amikacin, and imipenem resistance rates were 18% and 23.5%, respectively in ESBL-producing K. pneumoniae isolates.

Conclusion: All centers should identify their causative infectious agents, and and antibiotic resistance profiles, and formulate their antibiotherapy protocols, and investigate guiding current information.


[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | Arşiv | Yayın Arama | Yazarlara Bilgi | Etik Politikalar | İletişim